Freeline Therapeutics Holdings plc (FRLN)
Freeline Therapeutics Holdings plc operates in the Biotechnology industry of the Healthcare sector, headquartered in Stevenage, GB. The stock last traded at $6.49, up 0.15% on the session, giving a market capitalisation of $28.3M. On trailing twelve-month figures it carries a trailing P/E of -0.29, a net margin of 0.0%. Its beta of 0.66 implies it has historically moved less than the broad market.
Freeline Therapeutics Holdings plc is a biopharmaceutical company, currently in its clinical development phase, focused on creating groundbreaking gene therapies. These innovative treatments leverage adeno-associated virus (AAV) vector technology to tackle inherited, systemic, and severely debilitating genetic conditions. The company's leading therapeutic candidate, verbrinacogene setparvovec (FLT180a), is presently undergoing Phase 1/2 clinical trials for the management of hemophilia B in adult males. Furthermore, Freeline's pipeline features FLT190, which is also in Phase 1/2 clinical evaluation for treating Fabry disease, and FLT201, a gene therapy designed to target the liver for type 1 Gaucher disease, likewise progressing through Phase 1/2 trials. Beyond these specific programs, the company is actively pursuing research initiatives across a range of other systemic gene therapy indications. Freeline was established in 2015 and operates from its headquarters in Stevenage, United Kingdom.
Freeline Therapeutics Holdings plc is most often compared with the following Healthcare names: